Company
Oxford BioMedica PLC
LON:OXB
Oxford BioMedica is a biopharmaceutical company specialising in the development and commercialisation of innovative gene-based medicines. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange. Oxford BioMedica's products use genes as the mediators of a therapeutic effect and/or immune response. The company has a platform of gene delivery technologies, which are predominately based on highly engineered viral systems. Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how.
69 stories · page 1 of 4
AstraZeneca secures Covid-19 vaccine production amid safety concerns
The two companies first struck a supply and development deal for the vaccine in September 2020
UK Covid-19 cases jump by a third in a single week
The latest cases are thought to be caused by the Omicron variant